BioLargo (BLGO) LD Micro Main Event XIX Investor Conference summary
Event summary combining transcript, slides, and related documents.
LD Micro Main Event XIX Investor Conference summary
3 Feb, 2026Portfolio overview and innovation focus
Four primary commercial assets target human health, sustainability, and environmental challenges, each positioned as best-in-class solutions.
The company leverages partnerships and distribution to commercialize its technologies, focusing on filling market gaps.
The portfolio includes energy storage, medical technology, environmental odor/VOC control, and engineering services.
Each asset is at a different stage of market adoption, with some already generating significant revenue.
The company emphasizes risk management and forward-looking execution.
Asset performance and valuation
The energy storage business is considered the largest and most promising, with a scalable model based on selling battery factories rather than batteries.
Clyra Medical, with $20 million invested and a recent $95 million valuation, is preparing for a major national launch and justifies the current market cap.
PFAS treatment technology has a pipeline of over $200 million in contracts and is positioned as a cornerstone for environmental solutions.
The ONM odor control asset generated $50 million in top-line revenue last year but is undergoing repositioning after a licensing dispute.
Engineering services support innovation and have long-term contracts, including with the U.S. Air Force.
Technology and market differentiation
The salinity battery technology offers 20-year durability, high energy density (552 Wh/kg), and safety advantages over lithium and sodium-sulfur batteries.
The business model focuses on building and licensing battery factories globally, securing 19% carried interest and 6% royalty per factory.
Four MOUs for 11 factories are in place, with a Series B valuation target of $400 million.
The technology is positioned to address global supply chain risks and environmental concerns, appealing to sovereign wealth funds and local developers.
Patent strategy includes refiling and reliance on trade secrets for manufacturing processes.
Latest events from BioLargo
- Revenue fell sharply and losses widened as the company faces ongoing liquidity challenges.BLGO
Q2 2026 - Q1 2026 revenue plunged 66% year-over-year, driving a net loss and highlighting urgent capital needs.BLGO
Q1 2026 - Strategic partnership with Aquatech boosts PFAS commercialization and global project pipeline.BLGO
Status update - Registering 31.7M shares for resale; proceeds fund growth amid ongoing losses and litigation.BLGO
Registration filing - Registering 30M shares for resale under a $10M equity line to fund cleantech growth.BLGO
Registration filing - Revenue fell to $7.77M with a $15.19M loss, but growth catalysts and capital raises drive 2026 outlook.BLGO
Q4 2025 - Net loss widened to $11M on sharply lower revenue and a major customer default, raising going concern doubts.BLGO
Q3 2025 - Advanced PFAS and odor control tech fuel growth and global expansion in environmental markets.BLGO
11th Annual Waste and Environmental Symposium - Major product launches and tech advances drive rapid growth and high-value partnerships.BLGO
15th Annual LD Micro Invitational 2025